

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

UNAUDITED FINANCIAL RESULTS OF CR PHARMACEUTICAL HOLDINGS FOR THE SIX MONTHS ENDED 30 JUNE 2026 IN RELATION TO ISSUANCE OF MEDIUM TERM NOTES AND CORPORATE BONDS IN THE PRC

Reference is made to: (i) the announcement dated 29 May 2026 in relation to, among others, the proposed issuance of medium term notes in the PRC by China Resources Pharmaceutical Holdings Company Limited (華潤醫藥控股有限公司) (“**CR Pharmaceutical Holdings**”), a wholly owned subsidiary of the Company; (ii) the announcement dated 22 July 2026 in relation to, among others, the completion of the issuance of the first tranche of medium term notes for the year of 2026 in the PRC by CR Pharmaceutical Holdings; (iii) the announcement dated 29 July 2026 in relation to, among others, the completion of the issuance of the second tranche of medium term notes for the year of 2026 in the PRC by CR Pharmaceutical Holdings; and (iv) the announcement dated 16 April 2026 in relation to, among others, the completion of the issuance of the first tranche of corporate bonds in 2026 in the PRC by CR Pharmaceutical Holdings (the “**Announcements**”). Capitalised terms used herein shall have the same meanings as those defined in the Announcements unless stated otherwise herein.

In accordance with the relevant rules and regulations in the PRC and in connection with its issuance of medium term notes and corporate bonds in the PRC, CR Pharmaceutical Holdings has published its unaudited financial statements for the six months ended 30 June 2026 on the websites of China Money and Shanghai Clearing House in connection with the medium term notes, and on the website of the Shanghai Stock Exchange in connection with the corporate bonds.

The unaudited financial statements of CR Pharmaceutical Holdings for the six months ended 30 June 2026 (the “**Unaudited Financial Statements of CR Pharmaceutical Holdings**”) are enclosed to this announcement for the Company’s shareholders’ information only. The Unaudited Financial Statements of CR Pharmaceutical Holdings were prepared in Chinese and have been translated for publication in English and Chinese. In the event of any inconsistency between the two versions, the Chinese version shall prevail. In addition, the Unaudited Financial Statements of CR Pharmaceutical Holdings have been prepared in accordance with the PRC Generally Accepted Accounting Principles, have not been reviewed or audited by the Company’s auditors, and may require adjustments during the course of auditing. Such financial information is limited to CR Pharmaceutical Holdings only and does not represent or provide a complete view of the operational or financial status of the Group.

Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.

By order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 31 August 2026

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director, Mr. Cheng Jie and Mr. Liu Changan as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mdm. Zhang Jing and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive Directors.

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
CONSOLIDATED BALANCE SHEET
JUNE 2026

Unit: RMB

Item	Closing balance	Opening Balance	Item	Closing balance	Opening Balance
Current assets:			Current liabilities:		
Monetary fund	24,680,256,863.94	24,173,133,594.20	Short-term borrowings	44,692,759,737.02	40,737,794,364.47
Held-for-trading financial assets	10,879,098,404.39	12,069,041,094.95	Held-for-trading financial liabilities	-	-
Derivative financial assets	-	-	Notes payable and accounts payable	65,908,865,355.13	64,745,270,978.14
Notes receivable	374,454,089.28	586,483,121.19	Including: Notes payable	20,297,849,182.80	21,745,649,407.90
Accounts receivable	99,068,638,292.38	92,595,722,664.81	Accounts payable	45,611,016,172.33	42,999,621,570.24
Financing receivables	13,525,522,072.38	13,178,431,543.53	Receipts in advance	355,407,534.46	93,937,978.20
Prepayment	3,961,276,642.20	4,016,056,359.42	Contract liabilities	3,224,567,057.34	4,182,764,833.36
Other receivables	9,635,870,826.95	8,622,449,150.11	Staff remuneration payable	3,475,568,745.16	4,211,743,649.25
Including: Interest receivable	132,725.08	836,001.52	Including: Wages payable	861,876,546.30	1,080,675,958.90
Dividends receivable	0.00	0.00	Benefits payable	-	-
Inventory	45,080,474,462.02	43,276,039,279.45	Taxation payable	1,631,661,027.51	2,015,479,566.00
Including: Raw materials	3,634,045,013.21	3,202,249,965.23	Including: Tax payable	1,503,567,571.30	1,868,335,230.98
Goods in stock (finished products)	37,257,851,681.00	35,292,622,462.01	Other payables	24,635,830,504.12	21,431,783,225.55
Contract assets	41,872,924.04	55,493,546.50	Including: Interest payable	8,088,805.93	7,674,319.44
Assets held for sale	35,325,622.46	37,996,383.69	Dividends payable	8,116,592,298.36	4,732,832,203.56
Non-current assets due within one year	2,483,202,773.94	3,235,028,566.39	Insurance contract liabilities	-	-
Other current assets	2,147,064,651.73	2,301,374,310.71	Liabilities held for sale	-	-
			Non-current liabilities due within one year	8,374,185,320.59	8,110,938,853.35
			Other current liabilities	491,284,448.09	640,430,558.82
Total current assets	211,913,057,625.71	204,147,249,614.95	Total current liabilities	152,790,129,729.43	146,170,144,007.14
Non-current assets:			Non-current liabilities:		
Other debt investments	(0.00)	(0.00)	Long-term borrowings	6,461,295,929.71	11,149,853,384.60
Debt investments	83,280,094.96	79,280,094.96	Bonds payable	16,724,264,218.64	10,196,868,303.42
Long-term receivables	707,155,910.31	831,459,823.02	Long-term payables	404,335,926.29	408,549,258.29
Other equity instruments investments	10,942,625.57	10,942,625.57	Including: Long-term payables	160,785,920.00	160,785,920.00
Long-term equity investments	6,159,357,322.02	6,041,161,311.87	Special payables	243,550,006.29	247,763,338.29
Investment properties	368,892,763.15	353,339,799.28	Long-term employee remuneration payable	733,554,214.92	744,513,538.04
Other non-current financial assets	828,439,946.03	833,242,321.57	△Deferred revenue	798,590,348.64	781,520,816.97
Fixed assets	22,293,386,897.16	22,712,024,741.91	Estimated liabilities	1,362,459.98	1,321,000.65
Including: Disposal of fixed assets	11,523,424.85	9,711,113.40	Deferred income tax liabilities	1,795,841,755.54	1,892,214,582.04
Right-of-use assets	1,157,390,021.26	1,279,364,857.34	Lease liabilities	723,869,951.72	730,025,422.66
Construction in progress	3,097,613,615.41	2,587,796,563.58	Other non-current liabilities	3,814,940.00	3,814,940.00
Including: Construction materials	208,228.24	168,450.73	Including: Special reserve		
Biological assets for production	24,382,688.45	20,585,150.19	Total non-current liabilities	27,646,929,745.43	25,908,681,246.67
Oil and gas assets	-	-	Total liabilities	180,437,059,474.86	172,078,825,253.81

Item	Closing balance	Opening Balance	Item	Closing balance	Opening Balance
Intangible assets	13,253,860,993.21	13,309,319,592.85	Owners' equity (or shareholders' equity):		
Including: Land use right	5,018,407,870.15	4,882,090,433.67	Paid-in capital (equity)	21,007,000,000.00	21,007,000,000.00
Development expenses	2,939,120,770.30	2,960,721,894.91	State-owned capital		
Goodwill	24,354,410,933.42	24,342,133,911.47	Collective capital		
Long-term deferred expenses	461,200,577.98	473,179,715.38	Legal person capital		
Deferred income tax assets	2,512,484,138.50	2,347,164,484.40	Including: State-owned legal person capital		
Other non-current assets	4,284,042,317.57	3,974,805,304.11	Collectively-owned legal person capital		
Including: Contract assets	2,211,431.50	2,342,483.75	Individual's capital		
			Foreign capital		
			Capital surplus	185,353,464.71	165,697,373.12
			Less: Treasury shares		
			Other comprehensive income	33,388,819.91	46,898,136.52
			Including: Differences on translation of foreign currency	18,171,619.40	25,606,055.86
			Surplus reserves	972,961,454.68	972,961,454.68
Total non-current assets	82,535,961,615.29	82,156,522,192.41	Special reserves	4,992,022.37	5,027,989.57
			Undistributed profits	19,188,969,577.01	18,176,543,251.84
			Total equity attributable to owners of the parent company	41,392,665,338.68	40,374,128,205.73
			△ Minority interests	72,619,294,427.45	73,850,818,347.82
			Total owners' equity	114,011,959,766.13	114,224,946,553.55
Total assets	294,449,019,241.00	286,303,771,807.36	Total liabilities and owners' equity	294,449,019,241.00	286,303,771,807.36

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
CONSOLIDATED STATEMENT OF PROFIT OR LOSS
JANUARY TO JUNE 2026

Unit: RMB

Item	Accumulated amount for the year	Accumulated amount for the corresponding period of last year
I. Operating revenue	135,345,023,439.83	132,788,187,014.49
Including: Revenue from principal businesses	134,436,416,385.13	131,819,175,565.31
Revenue from other businesses	908,607,054.70	969,011,449.18
II. Operating costs	112,731,650,116.58	110,405,051,414.85
Including: Costs for principal businesses	112,340,862,015.89	109,852,909,737.49
Costs for other businesses	390,788,100.69	552,141,677.37
Tax and surcharge	600,880,475.65	579,908,148.25
Selling expenses	10,145,719,012.94	9,998,189,637.77
Management expenses	3,237,724,104.94	3,149,879,296.45
Including: Entertainment expenses	20,765,044.65	24,416,660.91
Research and development expenses	1,112,513,313.85	970,848,372.56
Finance costs	790,919,399.87	804,490,493.72
Including: Interest expenses	849,077,013.00	957,146,131.17
Interest income	146,470,116.34	205,354,012.40
Net loss from exchange (net gain is represented by “-”)	40,951,803.53	8,605,216.38
Other revenue	246,532,315.55	375,616,257.22
Gain from investment (loss is represented by “-”)	170,541,178.03	82,373,762.10
Including: Gains from investment in associates and joint ventures	146,236,168.09	127,376,865.49
Net gains from hedging exposure (loss is represented by “-”)	-	-
Add: Gains from changes in fair values (loss is represented by “-”)	16,460,592.44	61,246,808.99
Impairment losses of assets	128,567,398.52	227,651,013.87
Loss on credit impairment	641,013,734.75	624,663,311.88
Gains from disposal of assets	13,222,857.86	13,182,876.27
III. Operating profits (loss is represented by “-”)	6,402,792,826.60	6,559,925,029.73
Add: Non-operating income	98,750,504.65	113,180,345.42
Including: Gains from exchanging non-monetary assets	-	-
Government subsidies	-	14,833.18
Less: Non-operating expenses	55,156,861.42	64,875,650.61
Including: Loss on exchanging non-monetary assets	-	-

Item	Accumulated amount for the year	Accumulated amount for the corresponding period of last year
IV. Total profits (total loss is represented by “-”)	6,446,386,469.83	6,608,229,724.55
Less: Income tax expenses	1,270,860,231.83	1,365,709,737.55
V. Net profits (net loss is represented by “-”)	5,175,526,237.99	5,242,519,986.99
Including: Net profits of the absorbed party before business combination under common control		
Net profits attributable to the owners of the parent company	1,815,408,773.85	1,760,234,549.32
*Gains and losses of minority interests	3,294,742,464.14	3,449,760,437.67
Profit attributable to holders of perpetual capital instruments	65,375,000.00	32,525,000.00
VI. Other comprehensive income, net of tax	(83,813,071.95)	(4,748,111.08)
(I) Other comprehensive income that cannot be reclassified into profit or loss	(50,505,211.54)	1,779,097.42
Changes arising from remeasurement of defined benefit plan	2,704.45	—
Other comprehensive income that cannot be reclassified into profit or loss under the equity method	(50,507,915.99)	1,721,273.79
Changes in fair value of other equity instrument investments	(0.00)	57,823.63
(II) Other comprehensive income that may be reclassified to profit or loss	(33,307,860.40)	(6,527,208.51)
Other comprehensive income that may be reclassified to profit or loss under equity method	(50,351.81)	110,918.16
Changes in fair value of other debt investments	264.35	(12,986.68)
Amount included in other comprehensive income on reclassification of financial assets	—	—
Provision for credit impairment of other debt investment	—	—
Revaluation of fixed assets	—	—
Cash flows hedging reserve	—	—
Differences arising from translation of foreign currency	(33,255,068.49)	(6,625,139.98)
Others	(2,704.45)	0.00
VII. Total comprehensive income	5,091,713,166.05	5,237,771,875.91
VIII. Earnings per share:	—	—
Basic earnings per share	—	—
Diluted earnings per share	—	—
Add: Undistributed profit at the beginning of the year	18,174,155,591.48	14,950,877,474.62
Changes in accounting policies	—	(0.00)
Losses covered by surplus reserve	—	—
Other adjustment factors	—	0.00

Item	Accumulated amount for the year	Accumulated amount for the corresponding period of last year
IX. Distributable profit	19,989,564,365.34	16,711,112,023.95
Less: Appropriation of statutory surplus reserve	0.00	(0.01)
Appropriation for staff bonuses and benefit funds	–	–
Appropriation for reserve funds	–	–
Appropriation for company development funds	–	–
Others	–	–
X. Distributable profit attributable to investors	19,989,564,365.34	16,711,112,023.94
Preference shares dividends payable		
Appropriation of discretionary surplus reserve	–	–
Ordinary shares dividends payable	(800,000,000.00)	0.00
Ordinary shares dividends converted to equity	–	–
Others	(594,788.33)	0.00
XI. Undistributed profit	19,188,969,577.01	16,711,112,023.94

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
CONSOLIDATED STATEMENT OF CASH FLOWS
JANUARY TO JUNE 2026

Unit: RMB

Item	Accumulated amount for the year	Accumulated amount for the corresponding period of last year
I. Cash flows from operating activities:		
Cash received from the sales of goods and the rendering of services	138,716,345,824.69	135,507,491,291.93
Refund of taxes and levies	53,836,762.11	76,320,240.24
Cash received relating to other operating activities	7,217,432,178.84	7,347,921,499.59
Sub-total of cash inflows from operating activities	145,987,614,765.64	142,931,733,031.77
Cash paid for goods purchased and services received	115,423,162,404.46	113,538,539,355.47
Cash paid to and for employees	8,485,704,094.36	7,848,085,899.47
Payments of all types of taxes	5,554,564,618.32	5,476,681,095.13
Cash payments relating to other operating activities	15,075,392,607.24	14,493,601,581.10
Sub-total of cash outflows from operating activities	144,538,823,724.38	141,356,907,931.16
Net cash flow from operating activities	1,448,791,041.26	1,574,825,100.61
II. Cash Flow From Investing Activities:		
Cash received from investment recovery	26,769,699,100.39	17,053,655,729.22
Cash received from returns on investments	350,218,602.95	276,697,356.21
Net cash received from disposals of fixed assets, intangible assets and other long-term assets	318,456,176.62	46,060,223.24
Net cash received from disposals of subsidiaries and other operating units	–	11,911,840.85
Cash received relating to other investing activities	22,366,509.48	240,751,726.94
Sub-total of cash inflows from investing activities	27,460,740,389.44	17,629,076,876.46
Cash paid to acquire fixed assets, intangible assets and other long-term assets	1,632,714,643.05	1,506,537,871.93
Cash paid for investments	25,972,990,044.25	16,396,527,175.68
Net cash paid for acquisition of subsidiaries and other operational units	39,993,482.41	5,109,142,594.38
Cash payments relating to other investing activities	343,402,560.36	(479,208.49)
Sub-total of cash outflows from investing activities	27,989,100,730.07	23,011,728,433.50
Net cash flow from investing activities	(528,360,340.63)	(5,382,651,557.04)

Item	Accumulated amount for the year	Accumulated amount for the corresponding period of last year
III. Cash flow from financing activities:		
Cash received from capital contribution	19,492,000.00	114,593,600.00
Including: Cash received by subsidiaries from investments of minority shareholders		
Cash received from borrowings	32,342,296,506.12	40,604,790,301.78
Cash received from issuance of bonds	7,699,820,000.00	5,000,000,000.00
Cash payments relating to other financing activities	2,393,370,709.76	3,303,425,997.44
Sub-total of cash inflows from financing activities	42,454,979,215.88	49,022,809,899.22
Cash payments for debts settlement	38,146,011,708.03	38,956,630,236.10
Cash payments for distribution of dividends, profits, or interest expenses	2,694,062,264.11	2,458,372,059.72
Including: Dividends and profits paid by subsidiaries to minority shareholders	117,623,400.30	3,471,170.03
Cash payments relating to other financing activities	2,727,310,927.13	2,868,039,263.48
Sub-total of cash outflows from financing activities	43,567,384,899.27	44,283,041,559.30
Net cash flow from financing activities	(1,112,405,683.39)	4,739,768,339.93
IV. Effect of foreign exchange rate changes on cash and cash equivalents	(29,659,022.05)	1,460,601.10
V. Net increase in cash and cash equivalents	(221,634,004.81)	933,402,484.59
Add: Opening balance of cash and cash equivalent	15,765,241,201.49	16,323,306,375.52
VI. Closing balance of cash and cash equivalents	15,543,607,196.68	17,256,708,860.11

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
BALANCE SHEET
JUNE 2026

Unit: RMB

Item	Closing balance	Opening Balance	Item	Closing balance	Opening Balance
Current assets:			Current liabilities:		
Monetary fund	1,388,465,410.85	605,327,754.56	Short-term borrowings	1,006,471,111.11	1,501,386,666.66
Held-for-trading financial assets	1,557,938,847.27	1,605,145,283.04	Held-for-trading financial liabilities	-	-
Derivative financial assets	-	-	Notes payable and accounts payable	-	-
Notes receivable	-	-	Including: Notes payable	-	-
Accounts receivable	-	-	Accounts payable	-	-
Financing receivables	-	-	Receipts in advance	-	-
Prepayment	2,233,076.30	190,584.60	Contract liabilities	-	-
Other receivables	14,032,381,079.08	12,231,194,371.37	Staff remuneration payable	57,286,224.80	65,267,041.33
Including: Interest receivable	-	-	Including: Wages payable	-	-
Dividends receivable	8,867,748,449.32	6,572,748,449.32	Benefits payable	-	-
Inventory	-	-	Taxation payable	7,082,927.12	7,768,096.09
Including: Raw materials	-	-	Including: Tax payable	7,082,927.12	7,768,096.09
Goods in stock (finished products)	-	-	Other payables	1,579,112,939.90	1,151,408,704.22
Contract assets	-	-	Including: Interest payable	-	-
Assets held for sale	-	-	Dividends payable	800,000,000.00	-
Non-current assets due within one year	-	-	Insurance contract liabilities	-	-
Other current assets	2,413,301.74	2,379,335.64	Liabilities held for sale	-	-
			Non-current liabilities due within one year	1,312,034,422.37	2,312,950,189.86
			Other current liabilities	-	-
Total current assets	16,983,431,715.24	14,444,237,329.21	Total current liabilities	3,961,987,625.30	5,038,780,698.16
Non-current assets:			Non-current liabilities:		
Other debt investments	-	-	Long-term borrowings	205,125,187.04	222,082,502.61
Debt investments	-	-	Bonds payable	3,726,169,611.11	2,200,000,000.00
Long-term receivables	-	-	Long-term payables	-	-
Other equity instruments investments	-	-	Including: Long-term payables	-	-
Long-term equity investments	16,743,443,766.56	16,698,998,641.73	Special payables	-	-
Investment properties	-	-	Long-term employee remuneration payable	221,450,000.00	232,660,000.00
Other non-current financial assets	-	-	△Deferred revenue	-	-
Fixed assets	2,817,777.16	2,545,046.50	Estimated liabilities	-	-
Including: Disposal of fixed assets	-	-	Deferred income tax liabilities	-	-
Right-of-use assets	23,805,956.33	27,206,807.21	Lease liabilities	17,733,789.53	21,133,725.58
Construction in progress	-	260,030.96	Other non-current liabilities	-	-
Including: Construction materials	-	-	Including: Special reserve	-	-
Biological assets for production	-	-	Total non-current liabilities	4,170,478,587.68	2,675,876,228.19
Oil and gas assets	-	-	Total liabilities	8,132,466,212.98	7,714,656,926.35

Item	Closing balance	Opening Balance	Item	Closing balance	Opening Balance
Intangible assets	-	-	Owners' equity (or shareholders' equity):		
Including: Land use right	-	-	Paid-in capital (equity)	21,007,000,000.00	21,007,000,000.00
Development expenses	-	-	State-owned capital		
Goodwill	-	-	Collective capital		
Long-term deferred expenses	-	-	Legal person capital		
Deferred income tax assets	487,111.47	487,111.47	Including: State-owned legal person capital		
Other non-current assets	-	-	Collectively- owned legal person capital		
Including: Contract assets	-	-	Individual's capital		
			Foreign capital		
			Capital surplus	13,253,773.51	13,253,773.51
			Less: Treasury shares	-	-
			Other comprehensive income	74,610,416.58	74,610,416.58
			Including: Differences on translation of foreign currency	-	-
			Surplus reserves	1,213,171,274.84	1,213,171,274.84
Total non-current assets	16,770,554,611.52	16,729,497,637.87	Special reserves	-	-
			Undistributed profits	3,313,484,648.85	1,151,042,575.80
			Total equity attributable to owners of the parent company	25,621,520,113.78	23,459,078,040.73
			△Minority interests	-	-
			Total owners' equity	25,621,520,113.78	23,459,078,040.73
Total assets	33,753,986,326.76	31,173,734,967.08	Total liabilities and owners' equity	33,753,986,326.76	31,173,734,967.08

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
STATEMENT OF PROFIT OR LOSS
JANUARY TO JUNE 2026

Unit: RMB

Item	Accumulated amount for the year	Accumulated amount for the corresponding period of last year
I. Operating revenue	471,698.11	471,698.11
Including: Revenue from principal businesses	–	–
Revenue from other businesses	471,698.11	471,698.11
II. Operating costs	–	–
Including: Costs for principal businesses	–	–
Costs for other businesses	–	–
Tax and surcharge	703,149.03	291,648.33
Selling expenses	–	–
Management expenses	88,569,983.21	62,850,288.09
Including: Entertainment expenses	25,032.20	53,850.30
Research and development expenses	–	–
Finance costs	60,062,898.49	76,518,876.58
Including: Interest expenses	60,751,434.10	89,379,278.85
Interest income	722,620.46	13,964,556.56
Net Loss from exchange (net gain is represented by “–”)	(1,803,348.74)	(730,955.76)
Other revenue	–	166,065.61
Gain from investment (loss is represented by “–”)	3,094,598,204.60	391,330,397.95
Including: Gains from investment in associates and joint ventures	44,445,124.83	67,449,931.01
Net gains from hedging exposure (loss is represented by “–”)	–	–
Add: gains from changes in fair values (loss is represented by “–”)	16,575,594.73	17,559,802.84
Impairment losses of assets	–	–
Loss on credit impairment	–	32,069,477.09
Gains from disposal of assets	–	–
III. Operating profits (loss is represented by “–”)	2,962,309,466.71	237,797,674.42
Add: Non-operating income	675,606.34	20,411,740.24
Including: Gains from exchanging non-monetary assets	–	–
Government subsidies	–	–
Less: Non-operating expenses	543,000.00	2,950,000.00
Including: Loss on exchanging non-monetary assets	–	–

Item	Accumulated amount for the year	Accumulated amount for the corresponding period of last year
IV. Total profits (total loss is represented by “-”)	2,962,442,073.05	255,259,414.66
Less: Income tax expenses	–	(668,644.86)
V. Net profits (net loss is represented by “-”)	2,962,442,073.05	255,928,059.52
Including: Net gains of the absorbed party before business combination under common control		
Net profits attributable to the owners of the parent company	2,962,442,073.05	255,928,059.52
*Gains and losses of minority interests	–	–
Profit attributable to holders of perpetual capital instruments	–	–
VI. Other comprehensive income, net of tax	–	–
(I) Other comprehensive income that cannot be reclassified into profit and loss	–	–
Changes arising from remeasurement of defined benefit plan	–	–
Other comprehensive income that cannot be reclassified into profit or loss under the equity method	–	–
Changes in fair value of other equity instrument investments	–	–
(II) Other comprehensive income that may be reclassified to profit or loss	–	–
Other comprehensive income that may be reclassified to profit or loss under equity method	–	–
Change in fair value of other debt investments	–	–
Amount included in other comprehensive income on reclassification of financial assets	–	–
Provision for credit impairment of other debt investment	–	–
Revaluation of fixed assets	–	–
Cash flows hedging reserve	–	–
Exchange differences arising from translation of foreign currency	–	–
Others	–	–
VII. Total comprehensive income	2,962,442,073.05	255,928,059.52
VIII. Earnings per share:	–	–
Basic earnings per share	–	–
Diluted earnings per share	–	–
Add: undistributed profit at the beginning of the year	1,151,042,575.80	174,815,165.99
Changes in accounting policies	–	–
Losses covered by surplus reserve	–	–
Other adjustment factors	–	–

Item	Accumulated amount for the year	Accumulated amount for the corresponding period of last year
IX. Distributable profit	4,113,484,648.85	430,743,225.51
Less: Appropriation of statutory surplus reserve	–	–
Appropriation for staff bonuses and benefit funds	–	–
Appropriation for reserve funds	–	–
Appropriation for company development funds	–	–
Others	–	–
X. Distributable profit attributable to investors	4,113,484,648.85	430,743,225.51
Preference shares dividends payable		
Appropriation of discretionary surplus reserve	–	–
Ordinary shares dividends payable	(800,000,000.00)	–
Ordinary shares dividends converted to equity	–	–
Others	–	–
XI. Undistributed profit	3,313,484,648.85	430,743,225.51

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
STATEMENT OF CASH FLOWS
JANUARY TO JUNE 2026

Unit: RMB

Item	Accumulated amount for the year	Accumulated amount for the corresponding period of last year
I. Cash flow from operating activities:		
Cash received from the sales of goods and the rendering of services	514,910.54	500,000.00
Refund of taxes and levies	–	–
Cash received relating to other operating activities	1,083,985,528.22	356,901,376.13
Sub-total of cash inflows from operating activities	1,084,500,438.76	357,401,376.13
Cash paid for goods purchased and services received	627,108.13	5,950.95
Cash paid to and for employees	92,924,622.35	87,878,775.01
Payments of all types of taxes	703,149.03	330,437.57
Cash payments relating to other operating activities	853,212,884.91	440,882,839.45
Sub-total of cash outflows from operating activities	947,467,764.42	529,098,002.98
Net cash flow from operating activities	137,032,674.34	(171,696,626.85)
II. Cash flow from investing activities:		
Cash received from investment recovery	3,473,782,030.50	4,082,996,149.00
Cash received from returns on investments	755,153,079.77	393,725,893.66
Net cash received from disposals of fixed assets, intangible assets and other long-term assets	–	–
Net cash received from disposals of subsidiaries and other operating units	–	–
Cash received relating to other investing activities	–	802.28
Sub-total of cash inflows from investing activities	4,228,935,110.27	4,476,722,844.94
Cash paid to acquire fixed assets, intangible assets and other long-term assets	232,274.21	50,506.20
Cash paid for investments	3,540,000,000.00	1,680,000,000.00
Net cash paid for acquisition of subsidiaries and other operating units	–	371,636,801.95
Cash payments relating to other investing activities	–	–
Sub-total of cash outflows from investing activities	3,540,232,274.21	2,051,687,308.15
Net cash flow from investing activities	688,702,836.06	2,425,035,536.79

Item	Accumulated amount for the year	Accumulated amount for the corresponding period of last year
III. Cash flow from financing activities:		
Cash received from capital contribution	–	–
Including: Cash received by subsidiaries from investments of minority shareholders		
Cash received from borrowings	–	87,000,000.00
Cash received from issuance of bonds	1,500,000,000.00	–
Cash received relating to other financing activities	918,871,610.98	1,201,331,231.30
Sub-total of cash inflows from financing activities	2,418,871,610.98	1,288,331,231.30
Cash payments for debts settlement	1,511,866,667.00	2,000,000,000.00
Cash payments for distribution of dividends, profits, or interest expenses	34,346,990.16	140,808,008.61
Including: Dividends and profits paid by subsidiaries to minority shareholders	–	–
Cash payments relating to other financing activities	985,255,737.49	588,224,433.50
Sub-total of cash outflows from financing activities	2,531,469,394.65	2,729,032,442.11
Net cash flow from financing activities	(112,597,783.67)	(1,440,701,210.81)
IV. Effect of foreign exchange rate changes on cash and cash equivalents	(70.44)	(28.63)
V. Net increase in cash and cash equivalents	713,137,656.29	812,637,670.50
Add: Opening balance of cash and cash equivalents	575,327,754.56	540,934,149.52
VI. Closing balance of cash and cash equivalents	1,288,465,410.85	1,353,571,820.02